Climb Global Solutions (CLMB) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 results with net sales up 52% year-over-year to $119.3 million and adjusted gross billings up 65% to $465.2 million, driven by organic growth and acquisitions of DSS and DataSolutions.

• Net income more than doubled to $5.5 million ($1.19 per diluted share); adjusted net income also more than doubled to $7.1 million ($1.55 per diluted share).

• Adjusted EBITDA rose 96% to $9.9 million, with effective margin improving to 41%, reflecting strong organic growth and contributions from recent acquisitions.

• Double-digit organic growth achieved in both U.S. and Europe, with new vendor partnerships and expansion into Germany and the DACH region.

• Continued focus on leveraging global infrastructure for organic growth, accretive M&A, and unlocking synergies from acquisitions.

Financial highlights

• Adjusted Gross Billings rose 65% year-over-year to $465.2 million; net sales increased 52% to $119.3 million.

• Gross profit increased 70% to $24.3 million; gross profit margin on AGB improved to 5.2%.

• SG&A expenses rose to $13.9 million, mainly due to acquisitions, but declined as a percentage of adjusted gross billings to 3.0% from 3.6%.

• Adjusted EBITDA for Q3 2024: $9.9 million (+96% YoY); effective margin rose to 41%.

• Cash and cash equivalents at September 30, 2024: $22.1 million, down from $36.3 million at year-end due to acquisition and capital investments.

Outlook and guidance

• Expecting a strong Q4, consistent with historical seasonality and momentum from renewals and SaaS models.

• Management anticipates closing 2024 with another year of record results, leveraging global infrastructure and M&A.

• No anticipated changes in acquisition pace; plan remains one to two acquisitions per year, focusing on strategic fit and culture.

• Operational efficiencies from new ERP system expected by year-end 2024.

• Working capital needs anticipated to rise as business grows, but current cash and credit resources deemed sufficient for at least 12 months.